Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck stock fell in premarket trading Tuesday after the company said sales of its blockbuster HPV vaccine, Gardasil, declined ...

President Donald Trump’s Health and Human Services nominee said he will divest his interest in lawsuits against an HPV ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

U.S. drugmaker Merck & Co said on Wednesday (January 8, 2025) that its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration. The vaccine has been ...

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next ...

Merck issued guidance for 2025 that lags consensus ... after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine in China overshadowed a quarterly earnings beat.

Gardasil vaccine protects against cancer-causing human papilloma virus or HPV infections. The pause announcement comes a month after Merck received approval in China for use of the vaccine in males.